Earnings Feed
Start Free
RECURSION PHARMACEUTICALS, INC.·4

May 8, 4:59 PM ET

Gibson Christopher 4

4 · RECURSION PHARMACEUTICALS, INC. · Filed May 8, 2026

Research Summary

AI-generated summary of this filing

Updated

Recursion (RXRX) Director Christopher Gibson Sells 40,000 Shares

What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), reported several transactions on May 7, 2026. He sold 40,000 shares in an open-market sale at $3.37 each for proceeds of $134,800. The filing also shows conversions of derivative securities (60,000 shares acquired at $0.00; a separate derivative conversion recorded as a disposition for 60,000 shares) and a gift of 20,000 shares. The conversions relate to Class B common stock that is convertible into Class A common stock (see footnote F1).

Key Details

  • Transaction date: 2026-05-07 (Form filed 2026-05-08 — timely).
  • Open-market sale: 40,000 shares @ $3.37 = $134,800 (Sale code S). This sale was made pursuant to a Rule 10b5‑1 trading plan (footnote F2).
  • Derivative conversions: 60,000 shares acquired @ $0.00 (code C) and a separate C-coded disposition of 60,000 shares @ $0.00 (reported as a derivative transaction). Footnote F1: Class B shares are convertible into Class A shares at the holder’s option.
  • Gift: 20,000 shares (code G) @ $0.00. Gifts typically reflect personal/estate planning and are not a market sentiment signal.
  • Holdings/vehicles: Some shares are held by entities/trusts of which Gibson is a member/manager or trustee (LAHWRAN-3 LLC, LAHWRAN-4 LLC, Gibson Family Trust — footnotes F3–F5).
  • Shares owned after transaction: Not stated in the provided excerpt.

Context

  • The 10b5‑1 note indicates the sale was executed under a pre-established trading plan, which often means the sale was pre-scheduled rather than a discretionary trade.
  • Conversions of derivative securities here reflect converting Class B common into Class A common (no cash paid), not a cash purchase.
  • The gift of 20,000 shares is a personal transfer and should not be interpreted as an economic “sale” signal.

Insider Transaction Report

Form 4
Period: 2026-05-07
RECURSION PHARMACEUTICALS, INC.RXRX
Gibson Christopher
Director
Transactions
  • Conversion

    Class A Common Stock

    [F1][F2]
    2026-05-07+60,000→ 966,556 total
  • Sale

    Class A Common Stock

    [F2]
    2026-05-07$3.37/sh−40,000$134,800→ 926,556 total
  • Gift

    Class A Common Stock

    [F2]
    2026-05-07−20,000→ 906,556 total
  • Conversion

    Class B Common Stock

    [F1][F2]
    2026-05-07−60,000→ 4,343,334 total
    Exercise: $0.00→ Class A Common Stock (60,000 underlying)
Holdings

  • Class B Common Stock

    [F1][F3]
    (indirect: By LLC)
    Exercise: $0.00→ Class A Common Stock (0 underlying)
    386,000

  • Class B Common Stock

    [F1][F4]
    (indirect: By LLC)
    Exercise: $0.00→ Class A Common Stock (0 underlying)
    388,000

  • Class B Common Stock

    [F1][F5]
    (indirect: By Trust)
    Exercise: $0.00→ Class A Common Stock (0 underlying)
    50,000

  • Stock Option (Right to Buy)

    [F6]
    Exercise: $7.25Exp: 2035-02-03→ Class A Common Stock (0 underlying)
    1,050,567

  • Stock Option (Right to Buy)

    [F7]
    Exercise: $10.09Exp: 2034-02-09→ Class A Common Stock (0 underlying)
    666,898

  • Stock Option (Right to Buy)

    [F8]
    Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying)
    813,600

  • Stock Option (Right to Buy)

    [F9]
    Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying)
    399,002

  • Stock Option (Right to Buy)

    Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying)
    5,436

  • Stock Option (Right to Buy)

    [F10]
    Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (0 underlying)
    282,500
Footnotes (10)
  • [F1]Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
  • [F10]The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  • [F2]This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
  • [F3]The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
  • [F4]The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
  • [F5]The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
  • [F6]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  • [F7]The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  • [F8]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  • [F9]The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
Signature
/s/Jonathan Golightly, attorney-in-fact|2026-05-07

Documents

1 file
  • 4
    wk-form4_1778273958.xmlPrimary

    FORM 4